Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-02-23
2009-06-23
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S412000, C530S415000, C530S416000, C530S417000
Reexamination Certificate
active
07550567
ABSTRACT:
The present invention relates to a process for purifying fibrinogen, which comprises one or more process steps in which one or more contaminating proteins are depleted by negative chromatography and/or negative adsorption using cation exchanger, hydrophobic gel and/or dye gel. In addition, the invention relates to the fibrinogen which is obtained by the process of the invention and which is notable for improved stability, and to the production and use of pharmaceutical preparations comprising this fibrinogen.
REFERENCES:
patent: 4096136 (1978-06-01), Ayers et al.
patent: 4170590 (1979-10-01), Stephan et al.
patent: 4188318 (1980-02-01), Shanbrom
patent: 4210580 (1980-07-01), Amrani
patent: 4272523 (1981-06-01), Kotitschke et al.
patent: 4960757 (1990-10-01), Kumpe et al.
patent: 5043428 (1991-08-01), Heimburger et al.
patent: 5099003 (1992-03-01), Kotitschke et al.
patent: 5252709 (1993-10-01), Burnouf et al.
patent: 5723579 (1998-03-01), Buettner et al.
patent: 5773033 (1998-06-01), Cochrum et al.
patent: 5783663 (1998-07-01), Mondorf et al.
patent: 5834420 (1998-11-01), Laub et al.
patent: 6037457 (2000-03-01), Lord
patent: 6239261 (2001-05-01), Heimburger et al.
patent: 6582603 (2003-06-01), Suzuki et al.
patent: 6740736 (2004-05-01), McCreath
patent: 6960463 (2005-11-01), Kanellos et al.
patent: 0 366 946 (1990-05-01), None
patent: 0 408 029 (1991-01-01), None
patent: 0 789 030 (1997-08-01), None
patent: 1 551 928 (1979-09-01), None
patent: WO 89/12065 (1989-12-01), None
patent: WO 90/12803 (1990-11-01), None
patent: WO 93/05067 (1993-03-01), None
patent: WO 95/25748 (1995-09-01), None
patent: WO 99/05176 (1999-02-01), None
patent: WO 99/37680 (1999-07-01), None
patent: WO 99/51724 (1999-10-01), None
patent: WO 00/17234 (2000-03-01), None
patent: WO 00/17239 (2000-03-01), None
patent: WO 01/27623 (2001-04-01), None
patent: WO 01/48016 (2001-07-01), None
patent: WO 2004/007533 (2004-01-01), None
Vukovich, T. (Proceedings of the Serono Symposia (1979), Volume Date 1977, 15[Haemostasis Thromb.], 407-10).
Goheen et al., “Protein Losses in Ion-Exchange and Hydrophobic Interaction High-Performance Liquid Chromatography,”Journal of Chromatography A890:73-80 (2000).
Jennissen, “Critical Hydrophobicity HIC,” Derwent Abstract XP002342368 (2003).
European Search Report for EP 05 003017, Sep. 15, 2005.
Blombäck et al., “Purification of Human and Bovine Fibrinogen,”Arkiv För Kemi10:415-443 (1956).
Dempfle et al., “Purification of Human Plasma Fibrinogen by Chromatography on Protamine-Agarose,”Thrombosis Research46:19-27 (1987).
Deutsch et al., “Plasminogen: Purification from Human Plasma by Affinity Chromatography,”Science, 170:1095-1096 (1970).
Jakobsen et al., “A Modified Beta-Alanine Precipitation Procedure to Prepare Fibrinogen Free of Antithrombin-III and Plasminogen,”Thrombosis Research3:145-159 (1973).
Martinowitz et al., “Fibrin Tissue Adhesives,”Thrombosis and Haemostasis, 78:661-666, (1997).
Matsuda et al., “A Simple, Large Scale Method for Preparation of Plasminogen-Free Fibrinogen,”Thrombosis Research1:619-630 (1972).
Radosevich et al.; “Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use,”Vox Sanguinis, 72:133-143 (1997).
Schlag et al., “Epileptic Seizures Following Cortical Application of Fibrin Sealants Containing Tranexamic Acid in Rats,”Acta Neurochirurgica, 144:63-69 (2002).
Scott et al., “Human Factor Xla Cleaves Fibrinogen: Effects on Structure and Function,”Archives of Biochemistry and Biophysics, 249(2):480-488 (1986).
Sierra, “Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications,”Journal of Biomaterials Applications, 7:309-352 (1993).
Suzuki et al., “A Simple Technique for Purification of Fibrinogen from Plasma by Affinity Chromatography on Ristocetin-Agarose,”Thrombosis Research18:707-715 (1980).
Takeda, “Studies of the Metabolism and Distribution of Fibrinogen in Healthy Men with Autologous125I-labeled Fibrinogen,”Journal of Clinical Investigation45(1):103-111 (1966).
Vila et al., “A Rapid Method for Isolation of Fibrinogen from Human Plasma by Precipitation with Polyethylene Glycol 6,000,”Thrombosis Research39:651-656 (1985).
Vuento et al., “Purification of Fibronectin from Human Plasma by Affinity Chromatography Under Non-Denaturing Conditions,”Biochem. J. 183:331-337 (1979).
Derwent Abstract of WO 91/01808.
Derwent Abstract of EP 555135A.
English abstract of Kotitschke et al. (DE 29 03 131 A1, published Aug. 1979).
English abstract of Dazey et al. (EP 0 555 135 B1, published Aug. 1993).
English abstract of Seidel et al. (WO 91/01808, published Feb. 1991).
Feussner Annette
Gawantka Volker
Lemmer Joerg
Liebing Uwe
Metzner Hubert
CSL Behring GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Lukton David
LandOfFree
Fibrinogen purification does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibrinogen purification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrinogen purification will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149105